| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/10/2005 | US20050032852 1-(N-substituted sulfonamido),4-(substituted isooxazoly-4-yl)benzenes, e.g., N-ethyl-4-(5-methyl-3-phenylisoxazol-4-yl)-N-propionylbenzenesulfonamide; side effect reduction; solubility; stability; bioavailability, i.e., readily penetrate membranes; non-steroidal antiinflammatory agents; analgesics |
| 02/10/2005 | US20050032801 Compositions containing a ruthenium(III) complex and a heterocycle |
| 02/10/2005 | US20050032799 Treating a CNS disorder by orally administering to a patient a therapeutically effective amount of lamotrigine or a pharmaceutically acceptable derivative; for treatment of epilepsy, pain, edema, multiple sclerosis, psychological disorders, schizophrenia, bipolar disorders; side effect reduction |
| 02/10/2005 | US20050032781 Methods for administering active agents to CYP 2D6 sensitive patients |
| 02/10/2005 | US20050032762 injectable formulations comprising mixtures of testosterone ester such as testosterone undecanoate, in vehicles comprising castor oils and cosolvents; hormone replacement therapy and male contraception |
| 02/10/2005 | US20050032749 Pamidronate solution |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032716 controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests on domestic animals; contains a synergistic combination of a A83543 compound and a macrocyclic lactone |
| 02/10/2005 | US20050032698 includes a divalent cation (zinc chloride) in an amount effective to stabilize the hormone; osteoporosis |
| 02/10/2005 | US20050032688 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 02/10/2005 | US20050032680 Method of treatment of vulval vestibulitis |
| 02/10/2005 | US20050032676 Administering lipidated glycopeptide antibiotic and cyclodextrin, reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release |
| 02/10/2005 | US20050032183 Tumor necrosis factor receptor crystal protein for us in treatment and prevention of rheumatic, arthritic, psoriatic, and/or ankylosing spondylitis |
| 02/10/2005 | US20050031853 Pullulan film compositions |
| 02/10/2005 | US20050031775 High gloss film coating and stable solution therefor |
| 02/10/2005 | US20050031772 Ginger extract preparation |
| 02/10/2005 | US20050031716 Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| 02/10/2005 | US20050031714 Psyllium |
| 02/10/2005 | US20050031706 A bismuth containing agent , a non-clay-derived suspending agent; an stabilizer for reducing viscosity change during storage of the formulation and water |
| 02/10/2005 | US20050031705 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/10/2005 | US20050031700 In the form of a powder for suspension containing (a) an acid-labile proton pump inhibitor in micronized from; b) an antacid; and c) a gum as suspending agent |
| 02/10/2005 | US20050031699 Porous particles loaded with cosmetically or pharmaceutically active compounds |
| 02/10/2005 | US20050031698 Hydroxyapatite/collagen (HAp/Col) nanocomposite; a bioabsorbable capsule capable of enclosing growth factor, DNA enzyme therein |
| 02/10/2005 | US20050031697 Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| 02/10/2005 | US20050031696 Oral pharmaceutical formulations of acid-labile active ingredients and process for making same |
| 02/10/2005 | US20050031693 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | US20050031692 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | US20050031691 Gel stabilized nanoparticulate active agent compositions |
| 02/10/2005 | US20050031690 Multiple zones for containing an antiinflammatory agent/ns/ and water free solid prostaglandin dispersed in a hydroxypropyl methyl cellulose separately to mitigate gastric ulcerogenic effect of the NSAID |
| 02/10/2005 | US20050031688 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| 02/10/2005 | US20050031687 Enteric-coated proliposomal formulations for poorly water soluble drugs |
| 02/10/2005 | US20050031686 Gastroresistant tablets for alimentary, dietetic and therapeutic use |
| 02/10/2005 | US20050031685 Pharmaceutical composition for controlled release of a beta-lactam antibiotic |
| 02/10/2005 | US20050031684 Compression molded product of effervescent chlorinated isocyanuric acid |
| 02/10/2005 | US20050031683 Tablets containing an 8-alkoxyquinolonecarboxylic acid (gatifloxacin, moxifloxacin) antibacterial drug; mixing the drug with polyethylene glycol, adding an excipient comprising a diluent, a disintegrant, a glidant, or a lubricant and compressing the mixture into a tablet |
| 02/10/2005 | US20050031682 Modified calcium phosphate excipient |
| 02/10/2005 | US20050031681 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/10/2005 | US20050031679 Method for producing liposomal formulations of active ingredients |
| 02/10/2005 | US20050031678 Terazosin transdermal device & methods |
| 02/10/2005 | US20050031677 Sequential drug delivery systems |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031673 comprising a sorbent food body and a fluid carrier; enhanced caloric content and simulates the appearance of meat; moisture-reduced food product |
| 02/10/2005 | US20050031670 hunger-abating, low-calorie, and/or high energy edible composition comprising a bupropion compound and a food component |
| 02/10/2005 | US20050031669 a biodegradable polymer (glycolic acid-lactic acid copolymer) with a hydrophobic or hydrophobically enhanced drug; sustained release ocular implants; vision defects |
| 02/10/2005 | US20050031668 biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time; Parkinson's disease; erectile dysfunction and restless leg syndrome |
| 02/10/2005 | US20050031667 Implantable polymeric device for sustained release of dopamine agonist |
| 02/10/2005 | US20050031666 implant comprising a chemonucleolysis agent in solid form, wherein the implant, when placed into the nucleus pulposus of an intervertebral disc, releases the chemonucleolysis agent into the nuclear disc tissue surrounding the implant to proteolytically degrade the tissue |
| 02/10/2005 | US20050031665 Orthopedic hardware with a sustained release device configured to release a compound over an extended period of time and is attachable to a portion of the body |
| 02/10/2005 | US20050031659 comprising an emulsion of discontinuous oil phase, an aqueous continuous phase and emulsifier which comprises a non-alkoxylated water-soluble emulsification polymer; non-irritant to the skin and exhibit a reduced tendency to re-emulsify once broken |
| 02/10/2005 | US20050031652 Compositions and methods comprising memantine and polyanionic polymers |
| 02/10/2005 | US20050031651 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 02/10/2005 | US20050031650 Composition with gelling properties for the sustained delivery of bioactive substances |
| 02/10/2005 | US20050031629 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 02/10/2005 | US20050031580 Emulsifier for highly liquid W/O emulsion based on partly crosslinked polyglycerol esters of polyhydroxystearic acid |
| 02/10/2005 | US20050031568 Concentrated oil-in-water emulsions |
| 02/10/2005 | US20050031549 Compositions and methods for enhanced mucosal delivery of growth hormone |
| 02/10/2005 | US20050031548 Suspension aerosol formulations of pharmaceutical products |
| 02/10/2005 | US20050031547 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions |
| 02/10/2005 | US20050031546 Heat pressing a mixture of an active ingredient with abuse potential, a high strength polymer, and a wax into a controlled release dosage form |
| 02/10/2005 | US20050031540 Visco dye |
| 02/10/2005 | DE19906152B4 Wirkstoffhaltige Laminate für Transdermalsysteme Active substance laminates for transdermal |
| 02/10/2005 | DE10333443A1 Emulgator für dünnflüssige W/O-Emulsionen auf Basis von teilvernetzten Polyglycerinestern der Polyhydroxystearinsäure Emulsifier for highly liquid W / O emulsions based on partly crosslinked polyglycerol esters of polyhydroxystearic |
| 02/10/2005 | DE10158447B4 Ascorbinsäure-Solubilisat Ascorbic acid-solubilized |
| 02/10/2005 | DE10059318B4 Kosmetische Mittel enthaltend Alk(en)ylbernsteinsäurederivate Cosmetic products containing ylbernsteinsäurederivate alk (en) |
| 02/10/2005 | CA2769570A1 Calcium carbonate granulation |
| 02/10/2005 | CA2716449A1 Calcium carbonate granulation |
| 02/10/2005 | CA2546549A1 Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation |
| 02/10/2005 | CA2537899A1 Tissue-specific targeting of therapeutic and imaging agents to caveolae |
| 02/10/2005 | CA2535225A1 Methods for the stabilization of atorvastatin |
| 02/10/2005 | CA2534660A1 Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
| 02/10/2005 | CA2534371A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 02/10/2005 | CA2534354A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534318A1 Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agents |
| 02/10/2005 | CA2534238A1 Transdermal warfarin-containing delivery system |
| 02/10/2005 | CA2534214A1 Treatment of ocular disease |
| 02/10/2005 | CA2534129A1 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | CA2534074A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534073A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534042A1 Compositions for encapsulation and controlled release |
| 02/10/2005 | CA2534005A1 Methods of therapeutic treatment using amounts of retinoid components |
| 02/10/2005 | CA2533896A1 Improved stearate composition and method of production thereof |
| 02/10/2005 | CA2533833A1 Oral delivery system comprising a biliquid foam |
| 02/10/2005 | CA2533796A1 Crystalline tumor necrosis factor receptor 2 polypeptides |
| 02/10/2005 | CA2533740A1 Biliquid foams, stable dispersions thereof and a corresponding process of manufacturing |
| 02/10/2005 | CA2533150A1 A doxycycline metal complex in a solid dosage form |
| 02/10/2005 | CA2533128A1 Bioactive compositions comprising triazines |
| 02/10/2005 | CA2532931A1 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | CA2532904A1 Transdermal therapeutic system containing a pramipexol active agent |
| 02/10/2005 | CA2532251A1 Cci-779 lyophilized formulations |
| 02/10/2005 | CA2531279A1 Treatment and preventi0n of cardiovascular events |
| 02/10/2005 | CA2531227A1 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| 02/10/2005 | CA2527371A1 Method and device for improving the permeability of the human skin |
| 02/10/2005 | CA2526589A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 02/09/2005 | EP1505093A1 Hydrogel of (semi)interpenetrating network structure and process for producing the same |
| 02/09/2005 | EP1504778A2 Implantable pump for the treatment of obesity |
| 02/09/2005 | EP1504775A1 A coating for controlled release of a therapeutic agent |
| 02/09/2005 | EP1504765A1 Quickly soluble film preparations |
| 02/09/2005 | EP1504763A1 Traditional chinese pharmaceutical formulation for treatment of paradentosis, process for preparation and use thereof |
| 02/09/2005 | EP1504758A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |